First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL
These initial findings suggest that roflumilast may be an alternative agent able to inhibit BCR/PI3K activity and angiogenesis in DLBCL, and that the testing of Ro+R-CHOP in a larger series of genetically characterized tumors is warranted. This study was registered at ClinicalTrials.gov, number NCT03458546.
Authors
- Anand B. Karnad (ORCID: https://orcid.org/0000-0003-3420-5920)
- Paolo Albino Ferrari (ORCID: https://orcid.org/0000-0002-1788-5322)
- Carine Jaafar (ORCID: https://orcid.org/0000-0002-3107-573X)
- Gabriela Huelgas‐Morales (ORCID: https://orcid.org/0000-0002-9172-8253)
- Ricardo C.T. Aguiar (ORCID: https://orcid.org/0000-0002-8791-5849)
- Purushoth Ethiraj (ORCID: https://orcid.org/0000-0002-0679-6041)
- Kenneth N. Holder
- Adolfo Enrique Diaz Duque (ORCID: https://orcid.org/0009-0004-9941-7697)
- Patricia L. M. Dahia (ORCID: https://orcid.org/0000-0002-7757-370X)
- Matthew J. Butler (ORCID: https://orcid.org/0000-0002-8072-2614)
- Zhi‐Jun Qiu (ORCID: https://orcid.org/0000-0003-2226-6769)
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- South Texas Veterans Health Care System (US)
- Mays Cancer Center at UT Health San Antonio (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-18
- DOI
- https://doi.org/10.3390/cancers16223857
- Citations
- 2
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Cancer Prevention and Research Institute of Texas
- Leukemia and Lymphoma Society